Saval Corporation is a Chilean pharmaceutical company headquartered in Santiago, Chile. Founded in 1942, Saval has become one of the leading pharmaceutical companies in Chile, with a strong focus on central nervous system medications and a growing presence across South America[1].
| Attribute | Details |
|---|---|
| Headquarters | Santiago, Chile |
| Founded | 1942 |
| Products | 150+ pharmaceutical products |
| Presence | Chile, Peru, Bolivia, Ecuador |
Saval maintains a robust CNS portfolio with approximately 150+ pharmaceutical products across multiple therapeutic categories. The company's neuroscience division has grown significantly over the past decade, driven by increasing demand for neurodegenerative disease treatments in Latin America[1:1].
Saval provides essential Alzheimer's disease treatments including donepezil (generic and branded formulations), rivastigmine in both capsule and transdermal patch forms, memantine tablets, and galantamine. The company has focused on ensuring broad access to these medications across Chile and neighboring markets, recognizing the growing burden of Alzheimer's disease in the region.
The company offers comprehensive Parkinson's disease medications including standard and controlled-release levodopa/carbidopa formulations, pramipexole as a dopamine agonist, rotigotine transdermal patches for continuous dopaminergic stimulation, and monoamine oxidase-B inhibitors including selegiline and rasagiline. This comprehensive portfolio allows Saval to address various stages of Parkinson's disease management.
Beyond AD and PD, Saval addresses related neurological conditions including epilepsy medications (valproate, carbamazepine, levetiracetam), neuropathic pain treatments (pregabalin, gabapentin), and mood stabilizers for dementia-related behavioral symptoms. This broader neurological focus positions Saval as a key provider for CNS disorders in the Latin American market.
Saval maintains an active research and development program focused on neuroscience:
The company has invested significantly in developing generic versions of recently off-patent CNS medications, improving accessibility for Chilean and regional patients[2].
Saval distributes through a comprehensive regional network:
This regional presence makes Saval one of the most important CNS pharmaceutical providers in the Spanish-speaking Andean region.
| Country | Model | Facilities |
|---|---|---|
| Chile | Direct | Santiago HQ, 3 warehouses |
| Peru | Subsidiary | Lima office, 2 warehouses |
| Bolivia | Distribution | La Paz partner |
| Ecuador | Distribution | Quito partner |
Saval is a top-3 pharmaceutical company in Chile:
| Rank | Company | Revenue (CLP billion) |
|---|---|---|
| 1 | Saval | ~350 |
| 2 | Recalcine | ~280 |
| 3 | Andromaco | ~200 |
Saval operates GMP-certified manufacturing facilities: